August 27, 2018 — Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany. The CADScor System has been validated clinically to rule out CAD with 96-97 percent negative predictive value. The device is gaining interest and increased use across Germany and Denmark, key Swedish hospitals are testing the system and expansion in other European countries is under way. At ESC 2018, both in the exhibition booth and at a special session Aug. 28, there will be opportunities to get first-hand information about the CADScor System and to meet experts with experience from using the system in clinical practice.
The low diagnostic yield of current non-invasive testing in patients with suspected coronary artery disease has recently been described by Christina Therming et al.1 for a large hospital-based sample. Acarix CADScor System has been developed to add a reliable and simple diagnostic aid to the non-invasive diagnostic landscape that is easy to handle as a first line test in each clinical setting. The system is noninvasive, radiation-free and delivers a result in less than 10 minutes.
At ESC, visitors will hear how the performance of the CADScor System has recently been further documented. The system’s Algorithm v3 database contains 2,260 patients and performs with a sensitivity of 88.7 percent, specificity of 53.5 percent and a negative predictive value (NPV) of 95.9 percent for diagnosing CAD (stenosis >50 percent) versus non-CAD (stenosis < 30 percent). The NPV is 97.2 percent for diagnosing CAD (stenosis >50 percent) versus non-obstructive CAD (stenosis >30-< 50 percent) plus non-CAD (stenosis < 30 percent) (publication in preparation). Furthermore, a new study, Dan-NICAD II, is ongoing involving 1,500-2,000 patients with a low-to-intermediate likelihood of CAD from four Danish hospitals. The results are expected to further improve the CADScor System‘s already high NPV, to include patients aged < 40 years and to provide health economic documentation supporting its use as a fast and safe frontline assessment to reduce patient referrals.
For more information: www.acarix.com
1. Therming C., Galatius S., Heitmann M., et al. Low diagnostic yield of non-invasive testing in patients with suspected coronary artery disease: results from a large unselected hospital-based sample. European Heart Journal - Quality of Care and Clinical Outcomes, Dec. 18, 2017. https://doi.org/10.1093/ehjqcco/qcx048